40,623 Shares in Antares Pharma Inc (ATRS) Purchased by Mercer Global Advisors Inc. ADV

Mercer Global Advisors Inc. ADV acquired a new position in Antares Pharma Inc (NASDAQ:ATRS) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 40,623 shares of the specialty pharmaceutical company’s stock, valued at approximately $123,000.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Antares Pharma by 3.1% during the 4th quarter. BlackRock Inc. now owns 10,234,202 shares of the specialty pharmaceutical company’s stock worth $27,839,000 after buying an additional 304,945 shares during the period. Vanguard Group Inc grew its position in shares of Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc now owns 6,487,465 shares of the specialty pharmaceutical company’s stock worth $21,798,000 after buying an additional 84,181 shares during the period. Vanguard Group Inc. grew its position in shares of Antares Pharma by 1.3% during the 3rd quarter. Vanguard Group Inc. now owns 6,487,465 shares of the specialty pharmaceutical company’s stock worth $21,798,000 after buying an additional 84,181 shares during the period. Sargent Investment Group LLC acquired a new position in shares of Antares Pharma during the 4th quarter worth about $8,422,000. Finally, Northern Trust Corp grew its position in shares of Antares Pharma by 0.4% during the 4th quarter. Northern Trust Corp now owns 1,741,602 shares of the specialty pharmaceutical company’s stock worth $4,738,000 after buying an additional 6,868 shares during the period. Hedge funds and other institutional investors own 40.66% of the company’s stock.

Several equities analysts have recently issued reports on ATRS shares. Raymond James boosted their target price on Antares Pharma from $5.25 to $5.65 and gave the stock a “strong-buy” rating in a research report on Monday, March 4th. BidaskClub cut Antares Pharma from a “hold” rating to a “sell” rating in a report on Saturday, March 30th. TheStreet upgraded Antares Pharma from a “d” rating to a “c” rating in a report on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a $4.50 price objective on shares of Antares Pharma in a report on Monday, May 6th. Finally, Cowen initiated coverage on Antares Pharma in a report on Monday, February 25th. They set an “outperform” rating and a $1.99 price objective on the stock. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $4.83.

NASDAQ:ATRS opened at $2.85 on Friday. Antares Pharma Inc has a fifty-two week low of $2.40 and a fifty-two week high of $3.96. The company has a current ratio of 2.28, a quick ratio of 1.90 and a debt-to-equity ratio of 0.50. The stock has a market cap of $465.09 million, a PE ratio of -71.25 and a beta of 1.03.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. Antares Pharma had a negative return on equity of 17.94% and a negative net margin of 7.91%. The business had revenue of $23.29 million for the quarter, compared to analysts’ expectations of $17.46 million. As a group, equities analysts expect that Antares Pharma Inc will post -0.1 EPS for the current fiscal year.

In other news, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $2.67, for a total transaction of $80,100.00. Following the transaction, the director now owns 190,213 shares in the company, valued at approximately $507,868.71. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Leonard S. Jacob sold 92,078 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $3.00, for a total value of $276,234.00. Following the completion of the sale, the director now owns 301,970 shares in the company, valued at approximately $905,910. The disclosure for this sale can be found here. Insiders have sold a total of 322,078 shares of company stock worth $1,086,334 in the last quarter. 5.49% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.thestockobserver.com/2019/05/17/40623-shares-in-antares-pharma-inc-atrs-purchased-by-mercer-global-advisors-inc-adv.html.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: Penny Stocks

Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma Inc (NASDAQ:ATRS).

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.